Program
Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514
Its studies are mostly in Prostatic Neoplasms, led by GlaxoSmithKline.
Furthest: phase 2, since May 22, 20251 company-led study, 1 open or runningNext primary completion: Oct 26, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 2since May 22, 2025 | May 22, 2025 | Oct 26, 2027phase 2 · NCT06990880 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06990880 · 85 planned · United States, Canada, France and more
Ahead
- Oct 26, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT06990880
TargetBeta
“A bispecific immunoglobulin G-like T-cell engager (TCE) directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014rule | janux-therapeutics | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06990880Prostatic Neoplasms · United States, Canada, France and more | 2 | Recruiting | Oct 26, 2027 | 85 |
How it is read
Names in the registry
- “GSK5458514”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.